- Home
- EML vs ATYR Comparison
EML vs ATYR Comparison
Compare EML & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- ATYR
- Stock Information
- Founded
- EML 1858
- ATYR 2005
- Country
- EML United States
- ATYR United States
- Employees
- EML N/A
- ATYR N/A
- Industry
- EML Industrial Machinery/Components
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- ATYR Health Care
- Exchange
- EML Nasdaq
- ATYR Nasdaq
- Market Cap
- EML 191.3M
- ATYR 228.1M
- IPO Year
- EML N/A
- ATYR 2015
- Fundamental
- Price
- EML $27.93
- ATYR $3.58
- Analyst Decision
- EML
- ATYR Strong Buy
- Analyst Count
- EML 0
- ATYR 5
- Target Price
- EML N/A
- ATYR $19.25
- AVG Volume (30 Days)
- EML 10.1K
- ATYR 960.8K
- Earning Date
- EML 03-11-2025
- ATYR 03-13-2025
- Dividend Yield
- EML 1.59%
- ATYR N/A
- EPS Growth
- EML N/A
- ATYR N/A
- EPS
- EML N/A
- ATYR N/A
- Revenue
- EML $284,461,286.00
- ATYR $235,000.00
- Revenue This Year
- EML N/A
- ATYR N/A
- Revenue Next Year
- EML N/A
- ATYR $1,080.92
- P/E Ratio
- EML $13.80
- ATYR N/A
- Revenue Growth
- EML 7.70
- ATYR N/A
- 52 Week Low
- EML $22.63
- ATYR $1.42
- 52 Week High
- EML $35.78
- ATYR $4.23
- Technical
- Relative Strength Index (RSI)
- EML 54.79
- ATYR 52.84
- Support Level
- EML $25.31
- ATYR $3.46
- Resistance Level
- EML $29.39
- ATYR $3.83
- Average True Range (ATR)
- EML 0.77
- ATYR 0.24
- MACD
- EML 0.29
- ATYR -0.02
- Stochastic Oscillator
- EML 69.61
- ATYR 41.04
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.